Heteroatom Chemistry

Table of Contents

Table of Contents: 2022

  • Heteroatom Chemistry -
  • Special Issue
  • Volume 2022
  • - Article ID 7411957
  • - Research Article

Synthesized Phosphonium Compounds Demonstrate Resistant Modulatory and Antibiofilm Formation Activities against Some Pathogenic Bacteria

Cedric Dzidzor Kodjo Amengor | Cynthia Amaning Danquah | ... | Yussif Saaka
  • Heteroatom Chemistry -
  • Special Issue
  • Volume 2022
  • - Article ID 6078017
  • - Research Article

Synthesis, Structure, and Antifungal Activities of 3-(Difluoromethyl)-Pyrazole-4-Carboxylic Oxime Ester Derivatives

Bin Wang | Wei-Ting Chen | ... | Xing-Hai Liu
  • Heteroatom Chemistry -
  • Special Issue
  • Volume 2022
  • - Article ID 4678338
  • - Research Article

Isolation, Synthesis, and Fungicidal Activity of Isopropyl (3-methyl-1-oxo-1-((1-((4-(prop-2-yn-1-yloxy)phenyl)thio)propan-2-yl)amino)butan-2-yl)carbamate Diastereomers against Phytophthora capsici

Lei Tian | Yang Gao | ... | Xing-Hai Liu
  • Heteroatom Chemistry -
  • Special Issue
  • Volume 2022
  • - Article ID 5349279
  • - Review Article

Triazoles Synthesis & Applications as Nonsteroidal Aromatase Inhibitors for Hormone-Dependent Breast Cancer Treatment

Huda R. M. Rashdan | Ihsan A. Shehadi
  • Heteroatom Chemistry -
  • Special Issue
  • Volume 2022
  • - Article ID 8181543
  • - Research Article

Reexamining Povarov Reaction’s Scope and Limitation in the Generation of HCV-NS4A Peptidomimetics

Maan T. Khayat | Abdelsattar M. Omar | ... | Moustafa E. El-Araby
Heteroatom Chemistry
Publishing Collaboration
More info
Wiley Hindawi logo
 Journal metrics
See full report
Acceptance rate17%
Submission to final decision87 days
Acceptance to publication19 days
CiteScore3.200
Journal Citation Indicator0.210
Impact Factor0.3
 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.